Cramer’s lightning round: Riot Blockchain is not a buy

Cramer’s lightning round: Riot Blockchain is not a buy


Palantir: “If it can get to $10, then I would skedaddle. I hate to recommend it all the way down here because it’s near the bottom.”

Black Knight Inc: “The government is so fickle, I hesitate to recommend any arbitrage situation.”

Match Group Inc: “At $43? Really? I’m not going to recommend a sale of that thing.”

Manchester United PLC: “It’s not making money. … I have no catalyst, and when I have no catalyst, I just don’t know how to recommend.”

Cramer's lightning round: Riot Blockchain is not a buy

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.



Source

Walmart reports strong holiday growth, but earnings outlook falls short of estimates
Business

Walmart reports strong holiday growth, but earnings outlook falls short of estimates

Walmart said on Thursday that holiday-quarter sales rose nearly 6% and its quarterly earnings and revenue surpassed Wall Street’s expectations as gains in e-commerce, advertising and its third-party marketplace boosted its business. For the full current fiscal year, Walmart said it expects net sales to increase by 3.5% to 4.5% and adjusted earnings per share […]

Read More
Wayfair posts first annual sales gain since 2020, outperforms overall furniture market
Business

Wayfair posts first annual sales gain since 2020, outperforms overall furniture market

Wayfair store in Wilmette, Illinois. Courtesy: Wayfair Wayfair‘s annual sales grew last year for the first time since 2020 as the online furniture company continues to win over value-seeking consumers, the retailer announced Thursday.  In 2025, Wayfair revenue grew 5.1% to $12.5 billion. The gains follow a more than 1% year-over-year decline in 2024. The […]

Read More
FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals
Business

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

Food and Drug Administration Commissioner Marty Makary warned that the U.S. is falling behind China in early-stage drug development and called for reforms that could streamline the process for starting trials on new treatments.  In an interview with CNBC on Wednesday, Makary specifically pointed to three bottlenecks that he said cause the U.S. to fall […]

Read More